1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Coles, M. Bicknell, W. Watson, A.A. Fairlie, D.P. Craik, D.J. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US Biochemistry BICHAW 0033 0006-2960 37 11064 11077 10.1021/bi972979f 9693002 Solution structure of amyloid beta-peptide(1-40) in a water-micelle environment. Is the membrane-spanning domain where we think it is? 1998 10.2210/pdb1ba4/pdb pdb_00001ba4 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 4335.852 AMYLOID BETA-PEPTIDE ABETA 1 man polymer no no DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV A polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n human Homo sample 9606 Homo sapiens 32644 unidentified database_2 pdbx_database_status pdbx_struct_assembly pdbx_struct_oper_list repository Initial release Version format compliance Version format compliance Database references Derived calculations Other 1 0 1998-06-17 1 1 2008-03-24 1 2 2011-07-13 1 3 2022-02-16 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_database_status.process_site Y BNL 1998-04-07 REL REL LOW ENERGY, VIOLATIONS AND RMSD 50 10 NOESY TOCSY 5.1 298 K REFINEMENT DETAILS CAN BE FOUND IN JOURNAL CITATION ABOVE. SIMULATED ANNEALING USING NOE DISTANCE CONSTRAINTS BRUNGER refinement X-PLOR structure solution X-PLOR 500 Bruker AMX-500 600 Bruker DRX-500 750 Bruker AMX-600 750 Bruker DRX-750 ASP 1 n 1 ASP 1 A ALA 2 n 2 ALA 2 A GLU 3 n 3 GLU 3 A PHE 4 n 4 PHE 4 A ARG 5 n 5 ARG 5 A HIS 6 n 6 HIS 6 A ASP 7 n 7 ASP 7 A SER 8 n 8 SER 8 A GLY 9 n 9 GLY 9 A TYR 10 n 10 TYR 10 A GLU 11 n 11 GLU 11 A VAL 12 n 12 VAL 12 A HIS 13 n 13 HIS 13 A HIS 14 n 14 HIS 14 A GLN 15 n 15 GLN 15 A LYS 16 n 16 LYS 16 A LEU 17 n 17 LEU 17 A VAL 18 n 18 VAL 18 A PHE 19 n 19 PHE 19 A PHE 20 n 20 PHE 20 A ALA 21 n 21 ALA 21 A GLU 22 n 22 GLU 22 A ASP 23 n 23 ASP 23 A VAL 24 n 24 VAL 24 A GLY 25 n 25 GLY 25 A SER 26 n 26 SER 26 A ASN 27 n 27 ASN 27 A LYS 28 n 28 LYS 28 A GLY 29 n 29 GLY 29 A ALA 30 n 30 ALA 30 A ILE 31 n 31 ILE 31 A ILE 32 n 32 ILE 32 A GLY 33 n 33 GLY 33 A LEU 34 n 34 LEU 34 A MET 35 n 35 MET 35 A VAL 36 n 36 VAL 36 A GLY 37 n 37 GLY 37 A GLY 38 n 38 GLY 38 A VAL 39 n 39 VAL 39 A VAL 40 n 40 VAL 40 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 1 A PHE 4 176.64 103.89 1 A HIS 6 38.85 35.19 1 A GLU 11 69.64 -78.65 1 A HIS 13 -63.42 -74.88 1 A LYS 28 -36.60 -39.64 1 A VAL 39 -96.83 33.60 2 A HIS 6 38.25 29.04 3 A PHE 4 60.67 99.03 3 A HIS 6 -87.92 42.81 3 A HIS 13 -115.53 65.60 4 A PHE 4 -162.77 92.94 4 A ARG 5 -156.78 27.74 4 A HIS 6 -161.09 48.52 4 A GLU 11 -166.32 -6.01 4 A VAL 39 -92.22 33.60 5 A PHE 4 -147.51 59.09 5 A ASP 7 -65.45 -158.57 5 A HIS 13 -86.62 -78.97 6 A GLU 3 -102.90 48.06 6 A ARG 5 52.86 72.77 6 A HIS 6 34.25 39.35 6 A SER 8 47.35 -160.11 6 A TYR 10 62.22 140.21 6 A HIS 13 -75.11 -73.52 6 A HIS 14 -148.56 14.65 6 A VAL 39 -91.40 31.74 7 A ARG 5 -146.04 37.92 7 A HIS 6 -154.47 18.18 7 A VAL 12 -78.59 -152.41 7 A HIS 13 -120.59 -82.88 7 A HIS 14 -148.84 17.40 8 A ARG 5 64.42 82.00 8 A HIS 6 -88.85 48.97 8 A GLU 11 62.96 107.14 8 A HIS 13 -74.27 -73.86 8 A HIS 14 -148.48 11.52 8 A ASN 27 -61.60 -73.89 9 A ALA 2 -157.33 75.32 9 A HIS 6 -80.98 33.46 9 A TYR 10 -157.58 -67.50 9 A GLU 11 -168.61 -48.90 9 A VAL 12 -74.45 -166.77 9 A HIS 13 -61.23 -89.81 9 A HIS 14 -154.13 2.84 9 A ASN 27 -57.30 -71.75 10 A GLU 3 -81.09 -105.77 10 A PHE 4 -156.85 88.65 10 A ARG 5 48.66 24.90 10 A HIS 6 -113.08 -114.23 10 A ASP 7 -75.86 33.32 10 A SER 8 -162.47 26.16 10 A TYR 10 -83.65 -142.00 10 A GLU 11 -168.74 -42.39 10 A HIS 13 -153.21 5.62 10 A ASN 27 -58.53 -70.66 model building X-PLOR refinement X-PLOR phasing X-PLOR THE SOLUTION STRUCTURE OF AMYLOID BETA-PEPTIDE (1-40) IN A WATER-MICELLE ENVIRONMENT. IS THE MEMBRANE-SPANNING DOMAIN WHERE WE THINK IT IS? NMR, 10 STRUCTURES 1 Y N A GLN 15 A GLN 15 HELX_P A VAL 36 A VAL 36 1 1 22 GLYCOPROTEIN GLYCOPROTEIN, AMYLOID BETA-PEPTIDE, ALZHEIMER'S DISEASE, SDS-MICELLES A4_HUMAN UNP 1 1 P05067 MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGRLNMHMNVQNGKWDSDPSGTKTCIDTKEGILQYCQEVYPEL QITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVGEFVSDALLVPDKCKFLHQERMDVCETHLHWHTVAKETCSE KSTNLHDYGMLLPCGIDKFRGVEFVCCPLAEESDNVDSADAEEDDSDVWWGGADTDYADGSEDKVVEVAEEEEVAEVEEE EADDDEDDEDGDEVEEEAEEPYEEATERTTSIATTTTTTTESVEEVVREVCSEQAETGPCRAMISRWYFDVTEGKCAPFF YGGCGGNRNNFDTEEYCMAVCGSAMSQSLLKTTQEPLARDPVKLPTTAASTPDAVDKYLETPGDENEHAHFQKAKERLEA KHRERMSQVMREWEEAERQAKNLPKADKKAVIQHFQEKVESLEQEAANERQQLVETHMARVEAMLNDRRRLALENYITAL QAVPPRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKKAAQIRSQVMTHLRVIYERMNQSLSLLYNVPAVAEEIQD EVDELLQKEQNYSDDVLANMISEPRISYGNDALMPSLTETKTTVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPV DARPAADRGLTTRPGSGLTNIKTEEISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITL VMLKKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN 672 711 1BA4 1 40 P05067 A 1 1 40 1 P 1